Browsing Tag
systemic lupus erythematosus
9 posts
Saphnelo self-injection authorized in EU: AstraZeneca expands delivery options for lupus
Find out how AstraZeneca’s self-injection approval for Saphnelo could expand lupus treatment access and reshape biologic therapy delivery in Europe.
Fate Therapeutics reports encouraging Phase 1 progress for FT819 as off-the-shelf CAR T therapy targets durable lupus remission
Find out how Fate Therapeutics is advancing FT819 as an off-the-shelf CAR T therapy for lupus and why its Phase 1 data could reshape autoimmune treatment.
Cartesian Therapeutics reports 100% lupus response signal, setting up Descartes-08 for myositis expansion
Find out how Cartesian Therapeutics achieved a 100% lupus response and is driving Descartes-08 into myositis development today.
The next frontier: Can CAR T therapy become a one-time cure for autoimmune diseases?
Can CAR T therapy move beyond cancer and offer one-time remission for autoimmune disease? A deep look at early data, industry shifts, and clinical implications.
Fate Therapeutics unveils ACR 2025 results: FT819 off-the-shelf CAR T drives immune remodeling in lupus
Discover how Fate Therapeutics’ FT819 off-the-shelf CAR T therapy is reshaping lupus treatment through durable immune remodeling and long-term remission.
Can Bristol Myers Squibb’s CD19 NEX-T therapy replace lifelong immunosuppression? Early Phase 1 data raises the question
Bristol Myers Squibb’s new CAR T data suggests immune reset potential in lupus, systemic sclerosis, and inflammatory myopathies. Read how the paradigm may shift.
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE
Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in…
Kangpu wraps up phase 1 clinical trial of CRL4-CRBN modulator KPG-818
Chinese pharma company Kangpu Biopharmaceuticals said that it has wrapped up the first-in-human phase 1 clinical trial of…